Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ABX-CBL (Abgenix Inc).

K von Appen1

  • 1Schwerpunkt Nephrologie Medische Klinikum, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany. Kai.vonAppen@lrz.uni-muenchen.de

Idrugs : the Investigational Drugs Journal
|September 24, 2005
PubMed
Summary

ABX-CBL, an antibody, shows promise in treating graft versus host disease (GvHD) and preventing organ transplant rejection. Clinical trials indicate high response rates and good tolerability in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RenaGel (Geltex Pharmaceuticals Inc).

IDrugs : the investigational drugs journal·2005
Same author

[Myasthenia gravis. Opportunistic cytomegalovirus infection after long-term azathioprine therapy].

Der Nervenarzt·1999
Same author

[The differential diagnosis and therapy of hemolytic anemias after the transplantation of solid organs].

Urologiia i nefrologiia·1998
Same author

Early loss of renal transplants in patients with thrombophilia.

Transplantation·1998
Same author

[Chronic HIV- and chronic HBV infection with hematuria and proteinuria].

Deutsche medizinische Wochenschrift (1946)·1998
Same author

Structure and binding properties of serum albumin in uremic patients at different periods of hemodialysis.

Artificial organs·1998

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • Graft versus host disease (GvHD) and organ transplant rejection pose significant clinical challenges.
  • Existing treatments for GvHD and rejection have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy and safety of ABX-CBL (formerly CBL-1) in treating graft versus host disease (GvHD).
  • To assess the potential of ABX-CBL in preventing kidney and other organ transplant rejection.
  • To explore ABX-CBL's utility in managing autoimmune diseases and inflammation.

Main Methods:

  • Phase II clinical trials were conducted to assess ABX-CBL in patients with acute steroid-resistant GvHD.
  • A study involved 43 kidney transplant recipients who developed GvHD to evaluate ABX-CBL's effect on rejection.
  • Safety and tolerability were monitored throughout the trials.

Main Results:

  • In acute GvHD, ABX-CBL achieved a 90% overall response rate, with complete resolution in 50% of patients.
  • ABX-CBL effectively reversed initial rejection and prevented recurrence in kidney transplant patients.
  • The antibody was well-tolerated, with no serious adverse events reported and no exacerbation of post-transplant immunodeficiency.

Conclusions:

  • ABX-CBL demonstrates significant potential as a therapeutic agent for GvHD and transplant rejection.
  • The antibody's favorable safety profile supports its further investigation in clinical settings.
  • ABX-CBL may offer a new treatment option for patients with GvHD, transplant rejection, and potentially autoimmune conditions.

Related Experiment Videos